{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:55:28Z","timestamp":1789674928499,"version":"4.0.1"},"reference-count":62,"publisher":"The Royal Society","issue":"1721","license":[{"start":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T00:00:00Z","timestamp":1491782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/royalsociety.org\/journals\/ethics-policies\/data-sharing-mining\/"}],"content-domain":{"domain":["royalsocietypublishing.org"],"crossmark-restriction":true},"short-container-title":["Phil. Trans. R. Soc. B"],"published-print":{"date-parts":[[2017,5,26]]},"abstract":"<jats:p>Sporadic outbreaks of Ebola virus infection have been documented since the mid-Seventies and viral exposure can lead to lethal haemorrhagic fever with case fatalities as high as 90%. There is now a comprehensive body of data from both ongoing and completed clinical trials assessing various vaccine strategies, which were rapidly advanced through clinical trials in response to the 2013\u20132016 Ebola virus disease (EVD) public health emergency. Careful consideration of immunogenicity post vaccination is essential but has been somewhat stifled because of the wide array of immunological assays and outputs that have been used in the numerous clinical trials. We discuss here the different aspects of the immune assays currently used in the Phase I clinical trials for Ebola virus vaccines, and draw comparisons across the immune outputs where possible; various trials have examined both cellular and humoral immunity in European and African cohorts. Assessment of the safety data, the immunological outputs and the ease of field deployment for the various vaccine modalities will help both the scientific community and policy-makers prioritize and potentially license vaccine candidates. If this can be achieved, the next outbreak of Ebola virus, or other emerging pathogen, can be more readily contained and will not have such widespread and devastating consequences.<\/jats:p>\n                  <jats:p>This article is part of the themed issue \u2018The 2013\u20132016 West African Ebola epidemic: data, decision-making and disease control\u2019.<\/jats:p>","DOI":"10.1098\/rstb.2016.0295","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T20:10:27Z","timestamp":1491855027000},"page":"20160295","update-policy":"https:\/\/doi.org\/10.1098\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?"],"prefix":"10.1098","volume":"372","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-897X","authenticated-orcid":false,"given":"Teresa","family":"Lambe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"175","published-online":{"date-parts":[[2017,4,10]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"WHO. Situation Report: Ebola virus disease 10 June 2016. http:\/\/apps.who.int\/iris\/bitstream\/10665\/208883\/1\/ebolasitrep_10Jun2016_eng.pdf?ua=1. (accessed 10 June 2016)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71071-0"},{"key":"e_1_3_4_4_2","first-page":"1229","article-title":"Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA","volume":"159","author":"Kuhn JH","year":"2014","journal-title":"Arch. Virol"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.01.041"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3702"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2447"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/7422"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.10.006"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000837"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1502619112"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.094"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa8202"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00162-06"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.037"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu511"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62385-0"},{"key":"e_1_3_4_18_2","first-page":"150126054808000","article-title":"Chimpanzee adenovirus vector Ebola vaccine\u2014preliminary report","author":"Ledgerwood JE","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411627"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414216"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00486-7"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Tapia MD","year":"2016","journal-title":"Lancet Infect. Dis"},{"key":"e_1_3_4_23_2","first-page":"14","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe\u2014preliminary report","volume":"374","author":"Agnandji ST","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4218"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60553-0"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00154-1"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61591-3"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400446111"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70020-9"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02407-10"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.05.014"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1106319"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv040"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120721"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir349"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.071"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv082"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00561-09"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00096-J"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61117-5"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2129"},{"key":"e_1_3_4_42_2","volume-title":"WHO collaborative study to assess the suitability of an interim standard for antibodies to Ebola virus","author":"WHO","year":"2015"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01490-15"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2014.09.021"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00289"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir298"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(97)00212-3"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","unstructured":"Temperton NJ Wright E Scott SD. 2015 Retroviral pseudotypes\u2014from scientific tools to clinical utility. Chichester UK: eLS John Wiley & Sons Ltd.","DOI":"10.1002\/9780470015902.a0021549.pub2"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.6.2660-2664.2001"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60202"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1258"},{"key":"e_1_3_4_52_2","first-page":"135","article-title":"Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses","volume":"11","author":"Jahrling PB","year":"1996","journal-title":"Arch. Virol. Suppl"},{"key":"e_1_3_4_53_2","unstructured":"WHO. 2015 Blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens . Geneva Switzerland: WHO."},{"key":"e_1_3_4_54_2","unstructured":"WHO. 2015 Report of the SAGE Working Group on Ebola Vaccines and Vaccination with provisional recommendations for vaccination . Geneva Switzerland: WHO."},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.12.022"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep20617"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.20506\/rst.33.2.2311"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/874345"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00136-16"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2014.11.017"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.050"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.12.044"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009126"}],"container-title":["Philosophical Transactions of the Royal Society B: Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rstb.2016.0295","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/doi\/full-xml\/10.1098\/rstb.2016.0295","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rstb.2016.0295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:20:35Z","timestamp":1778620835000},"score":1,"resource":{"primary":{"URL":"http:\/\/royalsocietypublishing.org\/rstb\/article\/23162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,10]]},"references-count":62,"journal-issue":{"issue":"1721","published-print":{"date-parts":[[2017,5,26]]}},"alternative-id":["10.1098\/rstb.2016.0295"],"URL":"https:\/\/doi.org\/10.1098\/rstb.2016.0295","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,10]]},"assertion":[{"value":"2016-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}